Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 9:13:20406207221116577.
doi: 10.1177/20406207221116577. eCollection 2022.

Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations

Alexandra R Lovell  1 , Nadya Jammal  1 , Prithviraj Bose  2
Affiliations
Review

Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations

Alexandra R Lovell et al. Ther Adv Hematol. .

Abstract

Bruton's tyrosine kinase (BTK) inhibitors have dramatically changed the treatment of newly diagnosed and relapsed/refractory chronic lymphocytic leukemia (CLL). Ibrutinib, acalabrutinib, and zanubrutinib are Food and Drug Administration (FDA)-approved BTK inhibitors that have all demonstrated progression-free survival (PFS) benefit compared with chemoimmunotherapy. The efficacy of these agents compared to one another is under study; however, current data suggest they provide similar efficacy. Selectivity for BTK confers different adverse effect profiles, and longer follow-up and real-world use have characterized side effects over time. The choice of BTK inhibitor is largely patient-specific, and this review aims to highlight the differences among the agents and guide the choice of BTK inhibitor in clinical practice.

Keywords: Bruton’s Tyrosine Kinase inhibitors; chronic lymphocytic leukemia.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: None of the authors report any conflicts of interest relevant to this article. P.B. reports honoraria from Incyte, BMS, CTI Biopharma, Sierra Oncology, Abbvie, Novartis, Blueprint Medicines, Constellation (Morphosys), Karyopharm Therapeutics, and Pharma Essentia. P.B. reports research support from Incyte, BMS, CTI Biopharma, Blueprint Medicines, Cogent, Constellation (Morphosys), Kartos Therapeutics, Astellas, Pfizer, NS Pharma, and Promedior.

References

    1. Berglöf A, Turunen JJ, Gissberg O, et al.. Agammaglobulinemia: causative mutations and their implications for novel therapies. Expert Rev Clin Immunol 2013; 9: 1205–1221. - PubMed
    1. Vetrie D, Vorˇechovský I, Sideras P, et al.. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 1993; 361: 226–233. - PubMed
    1. Mohamed AJ, Yu L, Bäckesjö CM, et al.. Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev 2009; 228: 58–73. - PubMed
    1. Gomez-Rodriguez J, Readinger JA, Viorritto IC, et al.. Tec kinases, actin, and cell adhesion. Immunol Rev 2007; 218: 45–64. - PubMed
    1. Smith CIE. From identification of the BTK kinase to effective management of leukemia. Oncogene 2017; 36: 2045–2053. - PMC - PubMed

LinkOut - more resources